RxDoctor Payments Data

Diane Thomas, MD

Urogynecology and Reconstructive Pelvic Surgery · Merced, CANPI 1376882357

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,267 of the $6,377 with a category attached, or 66.9%. Intuitive Surgical accounts for 94.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $3,381 and has fallen 98.6% since, to $49 in 2025.

$6,377in general payments, 2019–2025

Across 30 payments — averaging $212.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Hologic Sales And Service, LLC$137
  • Axonics, Inc.$95
  • AbbVie$39
  • Sumitomo Pharma America, Inc.$33
  • Astellas Pharma US Inc$28
  • plus $37 from 2 others

What the payments were for

  • Travel & lodging$1,70327%
  • Food & beverage$4076%
  • Education$4,26767%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,377 in reported general payments places this provider in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$130,422
Medicare patients
282
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron126$101,678
GemtesaVibegron57$59,998
Solifenacin Succinate151$10,198
PremarinEstrogens, Conjugated17$7,265
Tolterodine Tartrate ErTolterodine Tartrate49$5,210
Estradiol71$3,287
Trospium Chloride44$2,014
Oxybutynin Chloride ErOxybutynin Chloride33$983
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$390
Fluconazole27$145
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$102
Ibuprofen14$44
Metronidazole13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$28$101,678126 claims
Sumitomo Pharma America, Inc.Gemtesa$33$59,99857 claims
PfizerPremarin$17$7,26517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

Other urogynecology and reconstructive pelvic surgery in Merced

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →